This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Stay up to date

Cardiovascular Diseases and Conditions Articles

Articles
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry
Shiyovich A, Berman AN, Besser SA, et al.
Journal:
J Am Heart Assoc

First published: May 18, 2024 DOI: 10.1161/JAHA.123.034493
View
- Share
Articles
Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use
Soroosh GP, Tasdighi E, Adhikari R, et al.
Journal:
Prog Cardiovasc Dis

First published: May 15, 2024 DOI: 10.1016/j.pcad.2024.05.004
View
- Share
Articles
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas F, Sener YZ, Golforoush PA, et al.
Journal:
Atherosclerosis

First published: May 14, 2024 DOI: 10.1016/j.atherosclerosis.2024.117579
View
- Share
Articles
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Kamstrup PR, Neely RDG, Nissen S, et al.
Journal:
Eur J Prev Cardiol

First published: May 11, 2024 DOI: 10.1093/eurjpc/zwae032
View
- Share
Articles
Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention
Sniderman AD, Dufresne L, Pencina KM, et al.
Journal:
Eur Heart J

First published: May 3, 2024 DOI: 10.1093/eurheartj/ehae258
View
- Share
Articles
Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN
Nicholls SJ, Nelson AJ, Ditmarsch M, et al.
Journal:
Am Heart J

First published: May 3, 2024 DOI: 10.1016/j.ahj.2024.05.002
View
- Share
Articles
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Bonaca MP, Bhatt DL, Simon T, et al.
Journal:
J Am Coll Cardiol

First published: April 30, 2024 DOI: 10.1016/j.jacc.2024.03.377
View
- Share
Articles
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
Burger PM, Bhatt DL, Dorresteijn JAN, et al.
Journal:
Eur Heart J Cardiovasc Pharmacother

First published: April 27, 2024 DOI: 10.1093/ehjcvp/pvae030
View
- Share
Articles
Empagliflozin after Acute Myocardial Infarction
Butler J, Jones WS, Udell JA, et al.
Journal:
N Engl J Med

First published: April 25, 2024 DOI: 10.1056/NEJMoa2314051
View
- Share
Articles
Targeting immune cell recruitment in atherosclerosis
Döring Y, van der Vorst EPC, Weber C
Journal:
Nat Rev Cardiol

First published: April 25, 2024 DOI: 10.1038/s41569-024-01023-z
View
- Share
Articles
Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus
Mszar R, Katz ME, Grandhi GR, et al.
Journal:
Curr Atheroscler Rep

First published: April 25, 2024 DOI: 10.1007/s11883-024-01202-w
View
- Share
Articles
Thoracic versus coronary calcification for atherosclerotic cardiovascular disease events prediction
Ichikawa K, Wang R, McClelland RL, et al.
Journal:
Heart

First published: April 23, 2024 DOI: 10.1136/heartjnl-2023-323838
View
- Share

1 2 3 … 23

How would you rate this content?

Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.

Cardiovascular Diseases and Conditions Articles

Articles

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

Shiyovich A, Berman AN, Besser SA, et al.

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Articles

Advancements in risk stratification and management strategies in primary cardiovascular prevention

Barkas F, Sener YZ, Golforoush PA, et al.

Articles

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Kamstrup PR, Neely RDG, Nissen S, et al.

Articles

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Sniderman AD, Dufresne L, Pencina KM, et al.

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Articles

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis

Bonaca MP, Bhatt DL, Simon T, et al.

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Articles

Targeting immune cell recruitment in atherosclerosis

Döring Y, van der Vorst EPC, Weber C

Articles

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Mszar R, Katz ME, Grandhi GR, et al.

Articles

Thoracic versus coronary calcification for atherosclerotic cardiovascular disease events prediction

Ichikawa K, Wang R, McClelland RL, et al.

Articles

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

Shiyovich A, Berman AN, Besser SA, et al.

Share

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Share

Articles

Advancements in risk stratification and management strategies in primary cardiovascular prevention

Barkas F, Sener YZ, Golforoush PA, et al.

Share

Articles

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Kamstrup PR, Neely RDG, Nissen S, et al.

Share

Articles

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Sniderman AD, Dufresne L, Pencina KM, et al.

Share

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Share

Articles

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis

Bonaca MP, Bhatt DL, Simon T, et al.

Share

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Share

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Share

Articles

Targeting immune cell recruitment in atherosclerosis

Döring Y, van der Vorst EPC, Weber C

Share

Articles

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Mszar R, Katz ME, Grandhi GR, et al.

Share

Articles

Thoracic versus coronary calcification for atherosclerotic cardiovascular disease events prediction

Ichikawa K, Wang R, McClelland RL, et al.

Share